Higher expression of CD147 and CD276 in patients with HER2+ BC and TNBC who received chemotherapy was associated with a lower complete response to chemotherapy, as supported by in independent cohorts of HER2+ BC and TNBC patients. This evidence concerns the gene CD276 and breast cancer.